Verona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 157,704 shares of the business's stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $9.30, for a total transaction of $1,466,647.20. Following the transaction, the chief executive officer now directly owns 13,798,864 shares in the company, valued at $128,329,435.20. This trade represents a 1.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
David Zaccardelli also recently made the following trade(s):
- On Thursday, May 29th, David Zaccardelli sold 208,696 shares of Verona Pharma stock. The stock was sold at an average price of $9.33, for a total transaction of $1,947,133.68.
- On Tuesday, May 27th, David Zaccardelli sold 33,600 shares of Verona Pharma stock. The stock was sold at an average price of $9.53, for a total transaction of $320,208.00.
- On Tuesday, April 29th, David Zaccardelli sold 90,360 shares of Verona Pharma stock. The shares were sold at an average price of $8.98, for a total transaction of $811,432.80.
Verona Pharma Stock Performance
VRNA traded up $3.34 during trading hours on Friday, reaching $80.83. The company's stock had a trading volume of 2,949,818 shares, compared to its average volume of 1,313,416. Verona Pharma plc has a 52 week low of $11.75 and a 52 week high of $81.73. The company's 50-day moving average is $65.59 and its 200-day moving average is $57.00. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03. The firm has a market cap of $6.55 billion, a PE ratio of -42.10 and a beta of 0.20.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million. On average, equities analysts forecast that Verona Pharma plc will post -1.95 EPS for the current year.
Analysts Set New Price Targets
Several research analysts recently issued reports on the stock. Roth Capital set a $83.00 price target on shares of Verona Pharma in a research report on Friday, February 28th. TD Cowen initiated coverage on Verona Pharma in a research note on Monday, April 28th. They issued a "buy" rating and a $100.00 price target for the company. Cantor Fitzgerald initiated coverage on Verona Pharma in a research note on Monday, April 21st. They set an "overweight" rating and a $80.00 target price for the company. Canaccord Genuity Group increased their target price on Verona Pharma from $44.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company upped their price target on Verona Pharma from $93.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 30th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $81.50.
View Our Latest Analysis on Verona Pharma
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. NBC Securities Inc. bought a new position in shares of Verona Pharma in the first quarter worth $34,000. Geneos Wealth Management Inc. boosted its stake in shares of Verona Pharma by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after purchasing an additional 193 shares in the last quarter. Vermillion Wealth Management Inc. acquired a new stake in shares of Verona Pharma during the fourth quarter valued at about $46,000. Acadian Asset Management LLC acquired a new stake in shares of Verona Pharma during the first quarter valued at about $48,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Verona Pharma in the first quarter worth approximately $58,000. Institutional investors own 85.88% of the company's stock.
About Verona Pharma
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
